NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
Sapience Therapeutics
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Merck Sharp & Dohme LLC
Jules Bordet Institute
National Cancer Institute (NCI)